Skip to content

CPAP Observance During the COVID-19 (SARS-CoV-2) Pandemic

CPAP Observance During the COVID-19 (SARS-CoV-2) Pandemic

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04775966
Acronym
COVADENE
Enrollment
8477
Registered
2021-03-01
Start date
2021-01-15
Completion date
2021-02-15
Last updated
2022-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep Apnea Syndromes

Keywords

Sleep Apnea, Positive Airway Pressure, telemedicine, COVID 19

Brief summary

The hypothesis of this work is that the COVID 19 pandemic and the associated lockdowns are likely to modify the adherence to positive airway pressure (PAP) treatments among patients with sleep apnea. Identifying these patients and identifying adherence trajectories over time would help mobilize human and telemedicine resources on the patients most in need.

Detailed description

The primary objective of this study is to compare PAP adherence during lockdowns in 2020 with the corresponding weeks during 2019.

Interventions

None listed

Sponsors

University Hospital, Montpellier
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patient treated/monitored by the Adene group * treated for sleep apnea syndrome (i.e., an initial apnoea hypopnea index (iAHI) ≥ 30/h or iAHI ≥ 15/h (and more than 10/h respiratory-effort-related arousal or cardio-metabolic/respiratory comorbidities) associated with symptoms from among sleepiness, tiredness, snoring, headaches, hypertension, reduced vigilance, libido disorders, nocturia, choking or suffocation during sleep, daytime tiredness) * Positive airway pressure (PAP)-treated for at least 4 months before January 1, 2019 * continuous PAP during 2019 * continuous PAP during 2020 * acceptance of PAP telemonitoring with consent given for data collection and data anonymization

Exclusion criteria

* less than 360 daily PAP tele-monitored data per year for 2019 * less than 360 daily PAP tele-monitored data per year for 2020

Design outcomes

Primary

MeasureTime frame
Change in positive airway pressure(PAP)-adherence during the first lockdown versus corresponding 2019 weeks (h/days)2020 versus 2019

Secondary

MeasureTime frame
Change in positive airway pressure(PAP)-adherence during the second lockdown versus corresponding 2019 weeks (h/days)2020 versus 2019
Change in PAP-adherence 2020 versus 2019 (h/days/weeks)2020 versus 2019
Change in the percentage of adherent patients (adherence > 4h/day/week) during the first lockdown versus corresponding 2019 weeks (h/days)2020 versus 2019
Change in the percentage of adherent patients (adherence > 4h/day/week) during the second lockdown versus corresponding 2019 weeks (h/days)2020 versus 2019
Change in patient adherence 2020 versus 2019 (%).2020 versus 2019

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026